BCR and leukemia: In Ph+ leukemia cases, either resistant to TKIs or not, PMIBcr/Abl‐R6 is thought to be able to kill Ph+ leukemia cells by dual targeting of both, MDM2 and Bcr/Abl (Figure 1).